Skip to main content

Table 1 Demographics and treatment related variables of all patients in this study (n = 55)

From: Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Variable Level n (%)
gender F 21 (38.2)
  M 34 (61.8)
stage IIIc 24 (43.6)
  IV 31 (56.4)
HLA A2 A2+ 34 (61.8)
  A2- 21 (38.2)
dosage 10 mg/kg 40 (72.7)
  3 mg/kg 15 (27.3)
irAE N 31 (56.4)
  Y 24 (43.6)
Outcome NED 35 (63.6)
  Relapse 20 (36.4)